A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Mechanism of Action
- JANX007 is a Tumor Activated T Cell Engager therapeutic targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer.
Purpose
In this study, the sponsor and investigators want to learn:
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- How the level of certain molecules (biomarkers) in your blood changes over time while receiving the study agent
Study Design
This is a dose escalation/expansion study and will be conducted in three parts. The purpose of Part 1 is to determine what is the safe dose of the study agent that can be administered and show signs of tumor killing capabilities. Dose escalation means that the amount of the study agent given will be increased in each group of research participants, to find the most appropriate dose for further study.
In the dose expansion part of the study, Part 2 and Part 3, a larger number of people receive the study agent dose determined to be appropriate in the dose escalation part of the study. The dose regimens will be selected based on the dose from Part 2 that showed the best tolerability and potential tumor destroying ability.
The study agent administration will be given weekly in cycles of 21 days. Alternative dosing schedules, every two weeks or every three weeks, (including a step dose regimen with JANX007 administered on Day 1, Day 4 and Day 8 in the first week of Cycle 1, called 4-day step) may be implemented depending on when you enroll into the study. Your doctor will let you know what dosing schedule you will follow.
This study involves observation / hospitalization in Medical City Dallas Hospital. After your first dose on Cycle 1 Day 1, you will be hospitalized in Medical City Dallas for 24-48 hours. If the first dose is well tolerated, you will only need to be observed for 2 hours after each infusion.
Location
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000